National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Tucatinib (Tukysa®). HTA ID: 22058

Tucatinib is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer wo have received at least two prior anti-HER2 treatment regimens.

 

NCPE Assessment Process Complete
Rapid review commissioned 23/08/2022
Rapid review completed 20/09/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tucatinib compared with the current standard of care.